Cleared Traditional

K121942 - ADENOVIRUS R-GENE US

K121942 is the FDA 510(k) clearance for ADENOVIRUS R-GENE US by Argene SA. It is a Class 2 Microbiology device (product code OCC) cleared through the Traditional 510(k) pathway after a 221-day FDA review.

K121942 · Argene SA · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 2013
Decision
221d
Days
Class 2
Risk

K121942 is an FDA 510(k) clearance for the ADENOVIRUS R-GENE US. Classified as Respiratory Virus Panel Nucleic Acid Assay System (product code OCC), Class II - Special Controls.

Submitted by Argene SA (Varilhes, FR). The FDA issued a Cleared decision on February 8, 2013 after a review of 221 days - an extended review cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3980 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Argene SA devices

Submission Details

510(k) Number K121942 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 02, 2012
Decision Date February 08, 2013
Days to Decision 221 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
119d slower than avg
Panel avg: 102d · This submission: 221d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code OCC Respiratory Virus Panel Nucleic Acid Assay System
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3980
Definition A Respiratory Viral Panel Multiplex Nucleic Acid Assay Is A Qualitative In Vitro Diagnostic Device Intended To Simultaneously Detect And Identify Multiple Viral Nucleic Acids Extracted From Human Respiratory Specimens Or Viral Culture. The Detection And Identification Of A Specific Viral Nucleic Acid From Individuals Exhibiting Signs And Symptoms Of Respiratory Infection Aids In The Diagnosis Of Respiratory Viral Infection When Used In Conjunction With Other Clinical And Laboratory Findings. The Device Is Intended For Detection And Identification Of A Combination Of The Following Viruses: Influenza A And Influenza B, Influenza A Subtype H1 And Influenza A Subtype H3, Respiratory Syncytial Virus Subtype A And Respiratory Syncytial Virus Subtype B, Parainfluenza 1, Parainfluenza 2, And Parainfluenza 3 Virus, Human Metapneumovirus, Rhinovirus, And Adenovirus.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - OCC Respiratory Virus Panel Nucleic Acid Assay System

All 32
Devices cleared under the same product code (OCC) and FDA review panel - the closest regulatory comparables to K121942.
XPERT FLU/RSV XC ASSAY
K142045 · Cepheid · Nov 2014
LYRA ADENOVIRUS ASSAY
K141931 · Quidel Corporation · Oct 2014
QUIDEL MOLECULAR RSV + HMPV ASSAY
K131813 · Quidel Corp. · Sep 2013
ABBOTT PLEX-ID FLU ASSAY
K121003 · Abbott Laboratories · Dec 2012
XPERT FLU
K123191 · Cepheid · Dec 2012
QUIDEL MOLECULAR INFLUENZA A + B ASSAY
K112172 · Quidel Corp. · Dec 2011